تداخلات ميثيل إرغونوفين

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

Do not use almotriptan tablets within 24 hours of an ergotamine-containing, or ergot-type medication, or of another 5-HT 1 agonist, e.g., another triptan ( 4.5 , 4.6 ) (نشرة ألموتريبتان، موانع الاستعمال)

• Recent use (i.e., within 24 hours) of another 5-hydroxytryptamine 1 (5-HT 1 ) agonist, ergotamine-containing medication, or ergot-type medication such as dihydroergotamine (DHE) or methysergide [see Drug Interactions (7.1) ] . (نشرة إليتريبتان، موانع الاستعمال)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

Avoid use of MARCAINE WITH EPINEPHRINE concomitantly with ergot-type oxytocic drugs [see Drug Interactions (7.3)]. (نشرة بوبيفاكايين، التحذيرات والاحتياطات)

Avoid use of MARCAINE WITH EPINEPHRINE concomitantly with ergot-type oxytocic drugs [see Drug Interactions (7.3) ] . (نشرة بوبيفاكايين وأدرينالين، التحذيرات والاحتياطات)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

Ergot derivatives: dihydroergotamine ergotamine methylergonovine ↑ dihydroergotamine ↑ ergotamine ↑ methylergonovine Concomitant administration with dihydroergotamine, ergotamine or methylergonovine is not recommended. (نشرة بيكتيغرافير وإمتريسيتابين وتينوفوفير ألافيناميد، التداخلات الدوائية)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

Recent use (i.e., within 24 hours) of another 5-HT 1 agonist, ergotamine-containing medication, or ergot-type medication (such as dihydroergotamine or methysergide) [see Drug Interactions (7.2 and 7.3) ] . (نشرة ريزاتريبتان، موانع الاستعمال)

…bowel disease [see Warnings and Precautions ( 5.5 ) ] Uncontrolled hypertension [see Warnings and Precautions ( 5.8 ) ] Recent use (i.e., within 24 hours) of another 5-HT 1 agonist, ergotamine-containing medication, or ergot-type medication (such as dihydroergotamine or methysergide) [see Drug Interactions ( 7.1 , 7.3 ) ] Concurrent administration of a monoamine… (نشرة زولميتريبتان، موانع الاستعمال)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

…Precautions (5.5)] • Ischemic bowel disease [see Warnings and Precautions (5.5)] • Uncontrolled hypertension [see Warnings and Precautions (5.8)] • Recent use (i.e., within 24 hours) of ergotamine-containing medication, ergot-type medication (such as dihydroergotamine or methysergide), or another 5-hydroxytryptamine 1 (5-HT 1 ) agonist [see Drug Interactions (7.1,… (نشرة سوماتريبتان، موانع الاستعمال)

Recent use (i.e., within 24 hours) of ergotamine-containing medication, ergot-type medication (such as dihydroergotamine or methysergide), or another 5-hydroxytryptamine1 (5-HT1) agonist [see Drug Interactions (7)]. (نشرة سوماتريبتان ونابروكسين، موانع الاستعمال)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

Recent use (i.e., within 24 hours) of another 5-HT 1 agonist, an ergotamine containing or ergot-type medication such as dihydroergotamine (DHE) or methysergide [see Drug Interactions (7.1 , 7.2) ]. (نشرة فروفاتريبتان، موانع الاستعمال)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

Vasopressors should not be used in the presence of ergot-type oxytocic drugs, since a severe persistent hypertension may occur. (نشرة كلوروبروكايين، التحذيرات)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

Avoid use of FLAVALTA concomitantly with ergot-type oxytocic drugs [see Drug Interactions (7.3) ]. (نشرة ليدوكايين وأدرينالين، التحذيرات والاحتياطات)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

Mepivacaine with epinephrine or other vasopressors should not be used concomitantly with ergot-type oxytocic drugs, because a severe persistent hypertension may occur. (نشرة ميبيفاكايين، التحذيرات)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

…Ischemic bowel disease [see Warnings and Precautions (5.5)] Uncontrolled hypertension [see Warnings and Precautions (5.8)] Recent use (i.e., within 24 hours) of another 5-HT 1 agonist, ergotamine-containing medication, ergot-type medication (such as dihydroergotamine or methysergide) [see Drug Interactions (7.1, 7.2)] Hypersensitivity to naratriptan tablets (angioedema… (نشرة ناراتريبتان، موانع الاستعمال)

Therefore, patients receiving sublingual nitroglycerin should avoid ergotamine and related drugs or be monitored for symptoms of ergotism if this is not possible. (نشرة نيتروغليسرين، التداخلات الدوائية)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

Beta-blockers Caution should be exercised when methylergonovine maleate is used concurrently with beta-blockers. (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

Beta-blockers Caution should be exercised when methylergonovine maleate is used concurrently with beta-blockers. (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

Caution should be exercised when methylergonovine maleate is used concurrently with other vasoconstrictors, ergot alkaloids, or prostaglandins. (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

CYP3A4 inducers Drugs (e.g. nevirapine, rifampin) that are strong inducers of CYP3A4 are likely to decrease the pharmacological action of methylergonovine maleate. (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

Caution should be exercised when methylergonovine maleate is used concurrently with other vasoconstrictors, ergot alkaloids, or prostaglandins. (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

Caution should be exercised when methylergonovine maleate is used concurrently with other vasoconstrictors, ergot alkaloids, or prostaglandins. (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

CYP3A4 inducers Drugs (e.g. nevirapine, rifampin) that are strong inducers of CYP3A4 are likely to decrease the pharmacological action of methylergonovine maleate. (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

Beta-blockers Caution should be exercised when methylergonovine maleate is used concurrently with beta-blockers. (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

Beta-blockers Caution should be exercised when methylergonovine maleate is used concurrently with beta-blockers. (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

Caution should be exercised when methylergonovine maleate is used concurrently with other vasoconstrictors, ergot alkaloids, or prostaglandins. (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

Coronary artery disease Patients with coronary artery disease or risk factors for coronary artery disease (e.g., smoking, obesity, diabetes, high cholesterol) may be more susceptible to developing myocardial ischemia and infarction associated with methylergonovine-induced vasospasm. (نشرة ميثيل إرغونوفين، التحذيرات)

Caution should be exercised when methylergonovine maleate is used concurrently with other vasoconstrictors, ergot alkaloids, or prostaglandins. (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

CYP3A4 inducers Drugs (e.g. nevirapine, rifampin) that are strong inducers of CYP3A4 are likely to decrease the pharmacological action of methylergonovine maleate. (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

Caution should be exercised when methylergonovine maleate is used concurrently with other vasoconstrictors, ergot alkaloids, or prostaglandins. (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

CYP3A4 inducers Drugs (e.g. nevirapine, rifampin) that are strong inducers of CYP3A4 are likely to decrease the pharmacological action of methylergonovine maleate. (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

Anesthetics Anesthetics like halothane and methoxyflurane may reduce the oxytocic potency of methylergonovine maleate. (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

Anesthetics Anesthetics like halothane and methoxyflurane may reduce the oxytocic potency of methylergonovine maleate. (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

Beta-blockers Caution should be exercised when methylergonovine maleate is used concurrently with beta-blockers. (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

Anesthetics Anesthetics like halothane and methoxyflurane may reduce the oxytocic potency of methylergonovine maleate. (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

Caution should be exercised when methylergonovine maleate is used concurrently with other vasoconstrictors, ergot alkaloids, or prostaglandins. (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

CYP3A4 Substrates Refer to the Prescribing Information for a CYP3A substrate where minimal concentration changes may lead to serious adverse reactions (e.g. rivaroxaban, calcineurin inhibitors, ergot derivatives, tyrosine kinase inhibitors) for the recommended dosage modification and/or monitoring. (نشرة بريماكين، التداخلات الدوائية)

Beta-blockers Caution should be exercised when methylergonovine maleate is used concurrently with beta-blockers. (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

CYP3A4 inducers Drugs (e.g. nevirapine, rifampin) that are strong inducers of CYP3A4 are likely to decrease the pharmacological action of methylergonovine maleate. (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

Caution should be exercised when methylergonovine maleate is used concurrently with other vasoconstrictors, ergot alkaloids, or prostaglandins. (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

Caution should be exercised when methylergonovine maleate is used concurrently with other vasoconstrictors, ergot alkaloids, or prostaglandins. (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

CYP3A4 inducers Drugs (e.g. nevirapine, rifampin) that are strong inducers of CYP3A4 are likely to decrease the pharmacological action of methylergonovine maleate. (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

Beta-blockers Caution should be exercised when methylergonovine maleate is used concurrently with beta-blockers. (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

Beta-blockers Caution should be exercised when methylergonovine maleate is used concurrently with beta-blockers. (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

Beta-blockers Caution should be exercised when methylergonovine maleate is used concurrently with beta-blockers. (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

Caution should be exercised when methylergonovine maleate is used concurrently with other vasoconstrictors, ergot alkaloids, or prostaglandins. (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

Beta-blockers Caution should be exercised when methylergonovine maleate is used concurrently with beta-blockers. (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

Caution should be exercised when methylergonovine maleate is used concurrently with other vasoconstrictors, ergot alkaloids, or prostaglandins. (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

CYP3A4 inducers Drugs (e.g. nevirapine, rifampin) that are strong inducers of CYP3A4 are likely to decrease the pharmacological action of methylergonovine maleate. (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

Beta-blockers Caution should be exercised when methylergonovine maleate is used concurrently with beta-blockers. (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

Beta-blockers Caution should be exercised when methylergonovine maleate is used concurrently with beta-blockers. (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

Anesthetics Anesthetics like halothane and methoxyflurane may reduce the oxytocic potency of methylergonovine maleate. (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

CYP3A4 inducers Drugs (e.g. nevirapine, rifampin) that are strong inducers of CYP3A4 are likely to decrease the pharmacological action of methylergonovine maleate. (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

CYP3A4 inducers Drugs (e.g. nevirapine, rifampin) that are strong inducers of CYP3A4 are likely to decrease the pharmacological action of methylergonovine maleate. (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

Caution should be exercised when methylergonovine maleate is used concurrently with other vasoconstrictors, ergot alkaloids, or prostaglandins. (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

Caution should be exercised when methylergonovine maleate is used concurrently with other vasoconstrictors, ergot alkaloids, or prostaglandins. (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

Caution should be exercised when methylergonovine maleate is used concurrently with other vasoconstrictors, ergot alkaloids, or prostaglandins. (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

CYP3A4 inducers Drugs (e.g. nevirapine, rifampin) that are strong inducers of CYP3A4 are likely to decrease the pharmacological action of methylergonovine maleate. (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

CYP3A4 inducers Drugs (e.g. nevirapine, rifampin) that are strong inducers of CYP3A4 are likely to decrease the pharmacological action of methylergonovine maleate. (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

CYP3A4 inducers Drugs (e.g. nevirapine, rifampin) that are strong inducers of CYP3A4 are likely to decrease the pharmacological action of methylergonovine maleate. (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

Beta-blockers Caution should be exercised when methylergonovine maleate is used concurrently with beta-blockers. (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

CYP3A4 inducers Drugs (e.g. nevirapine, rifampin) that are strong inducers of CYP3A4 are likely to decrease the pharmacological action of methylergonovine maleate. (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

Anesthetics Anesthetics like halothane and methoxyflurane may reduce the oxytocic potency of methylergonovine maleate. (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

CYP3A4 inducers Drugs (e.g. nevirapine, rifampin) that are strong inducers of CYP3A4 are likely to decrease the pharmacological action of methylergonovine maleate. (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

CYP3A4 inducers Drugs (e.g. nevirapine, rifampin) that are strong inducers of CYP3A4 are likely to decrease the pharmacological action of methylergonovine maleate. (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

CYP3A4 inducers Drugs (e.g. nevirapine, rifampin) that are strong inducers of CYP3A4 are likely to decrease the pharmacological action of methylergonovine maleate. (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

CYP3A4 inducers Drugs (e.g. nevirapine, rifampin) that are strong inducers of CYP3A4 are likely to decrease the pharmacological action of methylergonovine maleate. (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

CYP3A4 inducers Drugs (e.g. nevirapine, rifampin) that are strong inducers of CYP3A4 are likely to decrease the pharmacological action of methylergonovine maleate. (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

…drugs Tricyclic antidepressants Angiotensin, aldosterone Atropine Steroids, such as hydrocortisone Norepinephrine transporter inhibitors, such as atomoxetine Ergot alkaloids, such as methylergonovine maleate 7.2 Interactions that Antagonize the Pressor Effect The increasing blood pressure effect of BIORPHEN is decreased in patients receiving: α-adrenergic antagonists… (نشرة فينيليفرين، التداخلات الدوائية)

Caution should be exercised when methylergonovine maleate is used concurrently with other vasoconstrictors, ergot alkaloids, or prostaglandins. (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

CYP3A4 inducers Drugs (e.g. nevirapine, rifampin) that are strong inducers of CYP3A4 are likely to decrease the pharmacological action of methylergonovine maleate. (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

Caution should be exercised when methylergonovine maleate is used concurrently with other vasoconstrictors, ergot alkaloids, or prostaglandins. (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

Beta-blockers Caution should be exercised when methylergonovine maleate is used concurrently with beta-blockers. (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

CYP3A4 inducers Drugs (e.g. nevirapine, rifampin) that are strong inducers of CYP3A4 are likely to decrease the pharmacological action of methylergonovine maleate. (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

Anesthetics Anesthetics like halothane and methoxyflurane may reduce the oxytocic potency of methylergonovine maleate. (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

Beta-blockers Caution should be exercised when methylergonovine maleate is used concurrently with beta-blockers. (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

Caution should be exercised when methylergonovine maleate is used concurrently with other vasoconstrictors, ergot alkaloids, or prostaglandins. (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

CYP3A4 inducers Drugs (e.g. nevirapine, rifampin) that are strong inducers of CYP3A4 are likely to decrease the pharmacological action of methylergonovine maleate. (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

Concurrent administration of vasopressor drugs (for the treatment of hypotension related to obstetric blocks) and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents. (نشرة ليدوكايين، التداخلات الدوائية)

CYP3A4 inducers Drugs (e.g. nevirapine, rifampin) that are strong inducers of CYP3A4 are likely to decrease the pharmacological action of methylergonovine maleate. (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

CYP3A4 inducers Drugs (e.g. nevirapine, rifampin) that are strong inducers of CYP3A4 are likely to decrease the pharmacological action of methylergonovine maleate. (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

Beta-blockers Caution should be exercised when methylergonovine maleate is used concurrently with beta-blockers. (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

Beta-blockers Caution should be exercised when methylergonovine maleate is used concurrently with beta-blockers. (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

CYP3A4 inducers Drugs (e.g. nevirapine, rifampin) that are strong inducers of CYP3A4 are likely to decrease the pharmacological action of methylergonovine maleate. (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

Anesthetics Anesthetics like halothane and methoxyflurane may reduce the oxytocic potency of methylergonovine maleate. (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

Caution should be exercised when methylergonovine maleate is used concurrently with other vasoconstrictors, ergot alkaloids, or prostaglandins. (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

Beta-blockers Caution should be exercised when methylergonovine maleate is used concurrently with beta-blockers. (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

CYP3A4 inducers Drugs (e.g. nevirapine, rifampin) that are strong inducers of CYP3A4 are likely to decrease the pharmacological action of methylergonovine maleate. (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

Beta-blockers Caution should be exercised when methylergonovine maleate is used concurrently with beta-blockers. (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

CYP3A4 inducers Drugs (e.g. nevirapine, rifampin) that are strong inducers of CYP3A4 are likely to decrease the pharmacological action of methylergonovine maleate. (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

Drugs antagonizing pressor effects of epinephrine α-blockers, such as phentolamine Vasodilators, such as nitrates Diuretics Antihypertensives Ergot alkaloids Drugs potentiating pressor effects of epinephrine • Sympathomimetics • β-blockers, such as propranolol • Tricyclic anti-depressants • Monoamine oxidase (MAO) inhibitors • Catechol-O-methyl transferase (COMT)… (نشرة أدرينالين، التداخلات الدوائية)

Drug Interactions CYP 3A4 Inhibitors (e.g., Macrolide Antibiotics and Protease Inhibitors) There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g., dihydroergotamine and ergotamine) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of… (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

Examples of some of the strong CYP 3A4 inhibitors include saquinavir, grapefruit juice, nefazodone, macrolide antibiotics (e.g., troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

Pressor Effect with Concomitant Oxytocic Drugs Serious postpartum hypertension has been described in patients who received both a vasopressor (i.e., methoxamine, phenylephrine, ephedrine) and an oxytocic (i.e., methylergonovine, ergonovine) [ see Drug Interactions (7) ]. (نشرة إيفيدرين، التحذيرات والاحتياطات)

Examples of some of the strong CYP 3A4 inhibitors include saquinavir, grapefruit juice, nefazodone, macrolide antibiotics (e.g., troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

Fibrotic Complications Cases of retroperitoneal fibrosis, pulmonary infiltrates, pleural effusion, pleural thickening, pericarditis, and cardiac valvulopathy have been reported in patients treated with ergot-derived dopaminergic agents. (نشرة براميبيكسول، التحذيرات والاحتياطات)

Concurrent administration of vasopressor drugs and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents. (نشرة بريلوكايين وأدرينالين، التداخلات الدوائية)

Weak inhibitors include chlorzoxazone, cilostazol, and ranitidine. (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

Fibrotic Complications Cases of retroperitoneal fibrosis, pulmonary infiltrates, pleural effusion, pleural thickening, pericarditis, and cardiac valvulopathy have been reported in some patients treated with ergot-derived dopaminergic agents. (نشرة روبينيرول، التحذيرات والاحتياطات)

Weak inhibitors include chlorzoxazone, cilostazol, and ranitidine. (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

Moderate inhibitors include fluconazole, fluvoxamine and clotrimazole. (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

Methylergonovine maleate has been administered instead of vitamin K and Hepatitis B vaccine, medications which are routinely administered to the newborn. (نشرة ميثيل إرغونوفين، التحذيرات)

Methylergonovine maleate has been administered instead of vitamin K and Hepatitis B vaccine, medications which are routinely administered to the newborn. (نشرة ميثيل إرغونوفين، التحذيرات)

Drug Interactions CYP 3A4 Inhibitors (e.g., Macrolide Antibiotics and Protease Inhibitors) There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g., dihydroergotamine and ergotamine) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of… (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

Fibrotic Complications Cases of retroperitoneal fibrosis, pulmonary infiltrates, pleural effusion, and pleural thickening have been reported in some patients treated with ergot derived dopaminergic agents. (نشرة كاربيدوبا وليفودوبا وإنتاكابون، التحذيرات والاحتياطات)

Moderate inhibitors include fluconazole, fluvoxamine and clotrimazole. (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

Weak inhibitors include chlorzoxazone, cilostazol, and ranitidine. (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

Examples of some of the strong CYP 3A4 inhibitors include saquinavir, grapefruit juice, nefazodone, macrolide antibiotics (e.g., troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). (نشرة ميثيل إرغونوفين، التداخلات الدوائية)